Last reviewed · How we verify
Broxuridine (bromodeoxyuridine)
Broxuridine works by mimicking the structure of thymidine, a building block of DNA, and inhibiting the enzyme thymidine kinase, which is necessary for DNA replication.
Broxuridine, also known as bromodeoxyuridine, is a small molecule drug developed by the National Cancer Institute (NCI) that targets thymidine kinase, a key enzyme in DNA synthesis. It is classified as a broxuridine and works by inhibiting DNA replication, making it a potential treatment for various cancers. However, its commercial status and approved indications are unknown, and it has not been FDA-approved. As a result, its availability, safety, and efficacy are not well-established. Further research is needed to fully understand its potential as a cancer treatment.
At a glance
| Generic name | bromodeoxyuridine |
|---|---|
| Also known as | 5-BrdU, 5-bromodeoxyuridine, BrdU, broxuridine |
| Sponsor | National Cancer Institute (NCI) |
| Drug class | broxuridine |
| Target | Thymidine kinase, cytosolic, Thymidylate kinase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Imagine your body's cells are constantly making copies of their DNA to grow and repair themselves. Broxuridine gets in the way of this process by tricking the cell into thinking it's a normal building block of DNA. This prevents the cell from making new copies of its DNA, which can slow down or stop the growth of cancer cells.
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia (PHASE2)
- Genomic Instability in Vascular Surgeons
- Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients
- Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer (PHASE2)
- IUdR/BUdR Cell Cycle Labelling (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Broxuridine CI brief — competitive landscape report
- Broxuridine updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI